Rubin Lubomirov
Rubin Lubomirov publishes mostly in Oncology, Molecular Biology and Pharmacology, on topics such as Pharmacogenetics and Drug Metabolism, Lung Cancer Research Studies and HIV/AIDS drug development and treatment.
- World rank
- #2,552,612 of 7,710,434 ranked researchers
- Rank in Spain
- #56,049 of 204,306
- Works
- 54
- Citations
- 1.1k
- Citations per work
- 20.8
What does Rubin Lubomirov research?
Rubin Lubomirov's work is mostly in Medicine (38%), Biochemistry, Genetics and Molecular Biology (9%), Pharmacology, Toxicology and Pharmaceutics (8%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else2545.6%
- Health Sciences2037.5%
- Medicine2037.5%
- Life Sciences916.9%
- 1Oncology20% of their works
- 2Molecular Biology9% of their works
- 3Pharmacology8% of their works
- 4Infectious Diseases6% of their works
- 5Pulmonary and Respiratory Medicine6% of their works
- 6Cardiology and Cardiovascular Medicine6% of their works
Research topics
- Pharmacogenetics and Drug Metabolism
- Lung Cancer Research Studies
- HIV/AIDS drug development and treatment
- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- HIV-related health complications and treatments
- Cancer Treatment and Pharmacology
- Health Systems, Economic Evaluations, Quality of Life
Which keywords describe Rubin Lubomirov's research?
The keywords of their largest research topics: Clinical Trials, Targeted Therapy, Chemotherapy, Antiretroviral Therapy, HIV Infection, Cytochrome P450, Pharmacogenetics and Genomic Profiles.
- Taxanes
- Cost-effectiveness Analysis
- Inflammation
- Topoisomerases
- Integrase Inhibitors
- Drug Resistance
- Small-Cell Lung Cancer
- Genomic Profiles
- Cytochrome P450
- Antiretroviral Therapy
- Targeted Therapy
- Clinical Trials
- Chemotherapy
- HIV Infection
- Pharmacogenetics
- Quality of Life
- ALK Inhibitors
- EGFR Mutations
- DNA
- Cardiovascular Disease
- Chemotherapy-Induced Peripheral Neuropathy
- Health Utility Measures
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 22 words, with their numbers
- Clinical Trials192 topics
- Targeted Therapy192 topics
- Chemotherapy172 topics
- Antiretroviral Therapy152 topics
- HIV Infection152 topics
- Cytochrome P450121 topic
- Pharmacogenetics121 topic
- Genomic Profiles101 topic
- Quality of Life102 topics
- Small-Cell Lung Cancer101 topic
- ALK Inhibitors91 topic
- Drug Resistance91 topic
- EGFR Mutations91 topic
- Integrase Inhibitors91 topic
- DNA71 topic
- Topoisomerases71 topic
- Cardiovascular Disease61 topic
- Inflammation61 topic
- Chemotherapy-Induced Peripheral Neuropathy51 topic
- Cost-effectiveness Analysis51 topic
- Health Utility Measures51 topic
- Taxanes51 topic
Where does Rubin Lubomirov work?
Rubin Lubomirov's main affiliation in the publication record is PharmaMar (Spain), Spain.
How many publications and citations does Rubin Lubomirov have?
OpenAlex counts 54 works and 1,123 citations for Rubin Lubomirov, an h-index of 16, ranking #2,552,612 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Rubin Lubomirov. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.